1280786-83-5

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-1-isopropylindazole is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be incorporated into complex molecular structures, contributing to the development of novel therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Bromo-1-isopropylindazole is utilized as a precursor in the creation of new agrochemicals, enhancing crop protection and management through innovative chemical solutions.
Used in Organic Synthesis:
5-Bromo-1-isopropylindazole is employed as a versatile building block in organic synthesis, allowing for the construction of diverse chemical compounds with potential applications across various industries.
Used in Biological Research:
5-Bromo-1-isopropylindazole is used as a research tool in studying the effects of indazole derivatives on serotonin receptors, aiding in the understanding of their potential role in neurological and psychiatric conditions.
Used in Drug Development:
As a compound with potential biological activities, 5-Bromo-1-isopropylindazole is utilized in drug development for its capacity to influence specific biological targets, thereby contributing to the creation of new medicinal compounds.

Upstream product

• 53857-57-1 5-bromo-1H-indazole 
• 75-26-3 isopropyl bromide 
• 75-30-9 2-iodo-propane 

Relevant academic research and scientific papers

Discovery of (1 H-Pyrazolo[3,4- c]pyridin-5-yl)sulfonamide Analogues as Hepatitis B Virus Capsid Assembly Modulators by Conformation Constraint

Hepatitis B virus (HBV) capsid assembly modulators (CAMs) have been suggested to be effective anti-HBV agents in both preclinical and clinical studies. In addition to blocking HBV replication, CAMs could reduce the formation of covalently closed circular DNA (cccDNA), which accounts for the persistence of HBV infection. Here, we describe the discovery of (1H-indazole-5-yl)sulfonamides and (1H-pyrazolo[3,4-c]pyridin-5-yl)sulfonamides as new CAM chemotypes by constraining the conformation of the sulfamoylbenzamide derivatives. Lead optimization resulted in compound 56 with an EC50 value of 0.034 μM and good metabolic stability in mouse liver microsomes. To increase the solubility, the amino acid prodrug (65) and its citric acid salt (67) were prepared. Compound 67 dose dependently inhibited HBV replication in a hydrodynamic injection-based mouse model of HBV infection, while 56 did not show in vivo anti-HBV activity, likely owing to its suboptimal solubility. This class of compounds may serve as a starting point to develop novel anti-HBV drugs.

Compounds and their use in treatment on hepatitis B

The invention provides compounds, a pharmaceutical composition containing the compounds and an application of the compounds. The compound is a compound shown in a formula (I) or a stereoisomer, a tautomer, nitric oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound shown in the formula (I). The compound provided by the invention can interfere with the shell assembly process of hepatitis B virus, thereby inhibiting hepatitis B virus replication. Moreover, the compound has good absorption, relatively high biological activity and availability and low toxicity, particularly has relatively strong stability in vivo, is not easy to decompose and has long drug effect time, so that an effect of treating hepatitis B is achieved and the compound has a goodapplication prospect.

As a new polyphenylenepolymethylenepolyisocyanate deriv. SGLT2 inhibitor

A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).